Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.31.1 (
micrococcal nuclease
)
2,818
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The editing of apolipoprotein-B (apoB) mRNA involves the deamination of cytidine at nucleotide 6666 to uridine. The catalytic subunit of the editing enzyme,
apobec-1
, is a cytidine deaminase that requires other unidentified proteins to edit apoB mRNA in vitro. We partially purified an activity from baboon kidney that functionally complements
apobec-1
. The complementing activity was protease-sensitive and
micrococcal nuclease
-resistant, had a native molecular mass of 65 +/- 10 kDa on size exclusion chromatography, and sedimented at 4.5 S in glycerol gradients. Purified recombinant His6-tagged
apobec-1
immobilized on beads depleted >90% of the complementing activity from partially purified extracts. These beads edited apoB mRNA in vitro in the absence of exogenous
apobec-1
or complementing activity. A functional holoenzyme containing
apobec-1
and the complementing activity was eluted from the
apobec-1
-affinity resin using 0.5 M imidazole, whereas buffer containing 0.4 M KCl eluted only the complementing activity. The carboxyl-terminal 59 amino acids of
apobec-1
were not required for interaction with the complementing activity in vitro. Our results demonstrate that the complementing protein interacts directly with
apobec-1
in the absence of apoB mRNA.
...
PMID:Apobec-1 interacts with a 65-kDa complementing protein to edit apolipoprotein-B mRNA in vitro. 891 Apr 49